Andrew Ochieng, a survivor of visceral leishmaniasis, now combats this deadly parasitic disease across rural East Africa on his motorcycle, working to diagnose and treat neglected communities. His efforts, supported by the Drugs for Neglected Diseases Initiative (DNDi), highlight a critical grassroots fight against a neglected tropical disease that threatens millions.
As a child, Ochieng endured visceral leishmaniasis, suffering weeks of fever and undergoing painful treatments that left physical and emotional scars. This personal experience fuels his dedication to preventing others from similar ordeals. Visceral leishmaniasis, also known as Kala-azar, is the world’s second deadliest parasitic disease after malaria, transmitted by sandfly bites and causing symptoms like fever, weight loss, and organ swelling, with a 95% fatality rate if untreated. Over 600 million people are at risk globally, with most cases in East Africa.
Ochieng works as a community mobilizer for DNDi, crisscrossing the Kenya-Uganda border region on his motorbike to reach isolated villages. He sets up makeshift clinics under acacia trees, using rapid tests to diagnose the disease in minutes by checking for symptoms such as swollen spleens. His approach is vital in areas where healthcare access is limited and the disease is poorly understood, particularly among the nomadic Pokot ethnic group.
Challenges include the remoteness of the region, making patient follow-ups difficult as communities frequently move for water and grazing. Traditional healing practices, such as using dung and herbs, often delay proper medical care, and Ochieng encounters patients with marks from these rituals. Socioeconomic factors like malnutrition, poor sanitation, and climate change exacerbate the disease’s spread, affecting the poorest populations disproportionately.
Current treatments involve painful injections of drugs like sodium stibogluconate and paromomycin over 17 days, with risks of severe side effects on the heart and liver. DNDi is researching improved options, including clinical trials for combinations like miltefosine and paromomycin, which showed over 91% efficacy and fewer injections. However, logistical issues, such as refrigeration needs for newer drugs, hinder widespread use in resource-limited settings.
Outbreaks have occurred in Kenya and Uganda, with nearly four million Kenyans at risk during upsurges. Medical professionals like Dr. Patrick Sagaki at Amudat Hospital emphasize the need for faster case identification and better access, noting that regions like Bangladesh have made progress through awareness and timely interventions. Environmental changes, including deforestation and irrigation, also contribute to sandfly breeding, complicating control efforts.
Ochieng’s work has direct impact, as seen with patients like Chemket Selina, whom he diagnosed and transported to hospital, saving her life. He continues to monitor her children and others, advocating for early detection. His story underscores the importance of community-driven health initiatives in tackling neglected diseases, offering hope for reducing visceral leishmaniasis’s burden through sustained efforts and international support.
